Literature DB >> 25365064

Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.

H Ali1, J Palmer2, Z Eroglu1, T Stiller2, S H Thomas1, S Khaled1, S Shayani3, P Parker1, S J Forman1, R Nakamura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25365064      PMCID： PMC4318766          DOI： 10.1038/bmt.2014.245

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

2.  Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.

Authors:  Corey Cutler; Shuli Li; Vincent T Ho; John Koreth; Edwin Alyea; Robert J Soiffer; Joseph H Antin
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

3.  A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

Authors:  Roberto Rodriguez; Ryotaro Nakamura; Joycelynne M Palmer; Pablo Parker; Sepideh Shayani; Auyaporn Nademanee; David Snyder; Vinod Pullarkat; Neil Kogut; Joseph Rosenthal; Eileen Smith; Chatchada Karanes; Margaret O'Donnell; Amrita Y Krishnan; David Senitzer; Stephen J Forman
Journal:  Blood       Date:  2009-11-19       Impact factor: 22.113

4.  Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease.

Authors:  R Storb; H J Deeg; V Farewell; K Doney; F Appelbaum; P Beatty; W Bensinger; C D Buckner; R Clift; J Hansen
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

5.  Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.

Authors:  Sepideh Shayani; Joycelynne Palmer; Tracey Stiller; Xueli Liu; Sandra H Thomas; Tam Khuu; Pablo M Parker; Samer K Khaled; Stephen J Forman; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-15       Impact factor: 5.742

6.  Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.

Authors:  Corey Cutler; Haesook T Kim; Ephraim Hochberg; Vincent Ho; Edwin Alyea; Stephanie J Lee; David C Fisher; David Miklos; Jesse Levin; Stephen Sonis; Robert J Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2004-05       Impact factor: 5.742

7.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.

Authors:  R Storb; H J Deeg; J Whitehead; F Appelbaum; P Beatty; W Bensinger; C D Buckner; R Clift; K Doney; V Farewell
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

8.  Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study.

Authors:  M Schleuning; D Judith; Z Jedlickova; T Stübig; M Heshmat; H Baurmann; R Schwerdtfeger
Journal:  Bone Marrow Transplant       Date:  2008-11-17       Impact factor: 5.483

9.  Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

Authors:  Corey Cutler; Kristen Stevenson; Haesook T Kim; Paul Richardson; Vincent T Ho; Erica Linden; Carolyn Revta; Ruth Ebert; Diane Warren; Sung Choi; John Koreth; Philippe Armand; Edwin Alyea; Shelly Carter; Mary Horowitz; Joseph H Antin; Robert Soiffer
Journal:  Blood       Date:  2008-09-05       Impact factor: 22.113

10.  Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation.

Authors:  L Johnston; M Florek; R Armstrong; J S McCune; S Arai; J Brown; G Laport; R Lowsky; D Miklos; J Shizuru; K Sheehan; P Lavori; R Negrin
Journal:  Bone Marrow Transplant       Date:  2011-05-09       Impact factor: 5.483
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.